Treatment with fluoride or bisphosphonates prevents bone loss associated with colitis in the rat

• Published in: Calcified tissue international 2000-11, Vol.67 (5), p.373-377
• Main Authors: Lin, C L, Moniz, C, Chow, J W
• Format: Article
• Language: English
• Subjects: Animals; Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - pharmacology; Colitis - chemically induced; Colitis - complications; Diphosphonates - administration & dosage; Diphosphonates - pharmacology; Disease Models, Animal; Inflammatory Bowel Diseases - chemically induced; Inflammatory Bowel Diseases - complications; Intestine, Large - drug effects; Male; Osteoporosis - complications; Osteoporosis - prevention & control; Pamidronate; Rats; Rats, Wistar; Sodium Fluoride - administration & dosage; Sodium Fluoride - pharmacology; Tibia - drug effects; Trinitrobenzenesulfonic Acid - adverse effects
• ISSN: 0171-967X; 1432-0827
• DOI: 10.1007/s002230001162

Idiopathic inflammatory bowel disease (IBD) is associated with osteoporosis in over 30% of cases. We have previously shown that 2,4,6-trinitrobenzenesulphonic acid (TNBS)-induced colitis in rats is associated with considerable bone loss. In the current study we tested the ability of sodium fluoride (NaF) or the bisphosphonate pamidronate to prevent the bone loss associated with TNBS-induced colitis in 22-week-old male Wistar rats. As previously found, there was a 43% decrease in cancellous bone volume in rats with TNBS-induced colitis after 4 weeks. This was associated with marked suppression of the bone formation rate to less than 25% of control animals. Treatment with NaF had no effect on the severity of colitis, but the bone volume and bone formation rate were increased to levels indistinguishable from those of control animals. In animals treated with pamidronate, cancellous bone volume was also restored to that of control animals despite persistence of the colitis. In these animals there was marked suppression of bone formation, associated with suppression of bone resorption. This data shows the bone loss associated with colitis may be prevented by treatment with NaF or bisphosphonates without requiring improvement in severity of the colitis.